BMRN News

Key Factors

Recent Updates

Risk

Technical indicators show that the market is in a weak state and we need to pay attention to the risk of decline.
Recent technical signals are bearish with 3 bearish signals recorded and no bullish ones.
Market expectations tend to be pessimistic despite some differences in analyst ratings.

Generated at21:4804/02/2026by

Aime

Newswire

12:02

Biomarin's 15-minute chart triggers KDJ Golden Cross, bullish Marubozu pattern.

09:47

Biomarin's 15-Min Chart Shows RSI Overbought, KDJ Death Cross Signals.

11:21

Biomarin's 15-minute chart shows KDJ Golden Cross and bullish Marubozu signals.

03:27

BioMarin Pharmaceutical Inc. (BMRN) projects a rally with a potential upside of 54% despite a recent price target reduction. The company's acquisition of Amicus Therapeutics Inc. and its development pipeline make it an attractive investment opportunity.

15:02

Biomarin's 15min chart shows MACD Death Cross and narrowing Bollinger Bands.

About BMRN

Charts

SectorPharmaceutical

Established Date--

Listing Date23/07/1999

ExchangeNASDAQ Stock Exchange

Full-time Employees3221

Fiscal Year Ends31/12

Websitewww.bmrn.com

Security TypeCommon stock

Office address770 Lindaro Street, San Rafael, California 94901

Business

Introduction

Biomarin Pharmaceutical Inc., was incorporated in Delaware in October 1996 and commenced operations on March 21, 1997. The company is a global biotechnology company that transforms the promise of genetic discovery into drugs that have a profound impact on the lives of every patient. T. BioMarin selects product candidates for diseases and conditions representing significant unmet medical needs that have a good biological understanding and provide opportunities to be the first to market or offer advantages over existing products. The company's product portfolio consists of four approved products and multiple research candidates.